K M Myhr1, S I Mellgren. 1. Norwegian Multiple Sclerosis National Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway. kjell-morten.myhr@helse-bergen.no
Abstract
BACKGROUND: Multiple sclerosis (MS) is an immune-mediated inflammatory disease of the central nervous system (CNS) that usually is clinically characterized by repeated subacute relapses followed by remissions. Therapeutic strategies include corticosteroid treatment of relapses and immunomodulatory- or immunosuppressive treatment to prevent new relapses and progression of disability. OBJECTIVES: To review the evidences for the use of corticosteroids in the treatment of relapses in MS as well as its possible disease modifying potential. MATERIALS & METHODS: Available literature from PubMed search and personal experiences on corticosteroid treatment in multiple sclerosis were reviewed. RESULTS: High dose short-term oral or intravenous methylprednisolone for 3-5 days speed up recovery from relapses, but the treatment has no influence on the occurrence of new relapses or long-term disability. There is also some evidence that pulsed treatment with methylprednisolone have beneficial long-term effects in multiple sclerosis. CONCLUSION: Relapses with moderate to serious disability should be treated with high dose intravenous or oral methylprednisolone. More data is needed to determine long-term disease modifying effects of corticosteroids.
BACKGROUND:Multiple sclerosis (MS) is an immune-mediated inflammatory disease of the central nervous system (CNS) that usually is clinically characterized by repeated subacute relapses followed by remissions. Therapeutic strategies include corticosteroid treatment of relapses and immunomodulatory- or immunosuppressive treatment to prevent new relapses and progression of disability. OBJECTIVES: To review the evidences for the use of corticosteroids in the treatment of relapses in MS as well as its possible disease modifying potential. MATERIALS & METHODS: Available literature from PubMed search and personal experiences on corticosteroid treatment in multiple sclerosis were reviewed. RESULTS: High dose short-term oral or intravenous methylprednisolone for 3-5 days speed up recovery from relapses, but the treatment has no influence on the occurrence of new relapses or long-term disability. There is also some evidence that pulsed treatment with methylprednisolone have beneficial long-term effects in multiple sclerosis. CONCLUSION: Relapses with moderate to serious disability should be treated with high dose intravenous or oral methylprednisolone. More data is needed to determine long-term disease modifying effects of corticosteroids.
Authors: Matthew E Sweeney; Joyce G Slusser; Sharon G Lynch; Stephen H Benedict; Sharon L Garcia; Laura Rues; Steven M LeVine Journal: Int Immunopharmacol Date: 2011-07-30 Impact factor: 4.932
Authors: Elisabeth Calderón-Gómez; Vicky Lampropoulou; Ping Shen; Patricia Neves; Toralf Roch; Ulrik Stervbo; Sascha Rutz; Anja A Kühl; Frank L Heppner; Christoph Loddenkemper; Stephen M Anderton; Jean M Kanellopoulos; Pierre Charneau; Simon Fillatreau Journal: Eur J Immunol Date: 2011-05-25 Impact factor: 5.532
Authors: Regina Berkovich; Rohit Bakshi; Lilyana Amezcua; Robert C Axtell; Steven Y Cen; Shahamat Tauhid; Mohit Neema; Lawrence Steinman Journal: Ther Adv Neurol Disord Date: 2016-10-19 Impact factor: 6.570
Authors: Clare J Wilhelm; Joel G Hashimoto; Melissa L Roberts; Shelley H Bloom; Douglas K Beard; Kristine M Wiren Journal: Brain Res Date: 2015-01-16 Impact factor: 3.252